Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
Randomized Controlled Trial
[키워드] 1:1
acute respiratory syndrome
Adverse
analysed
antiviral activity
ARMS
collected
Complete
coronavirus
coronavirus disease
COVID-19
double-blind
dry cough
enrolled
event
Evidence
fatigue
Fever
first dose
hospitalisation
in vitro
Infection
Inflammation
interquartile range
Laboratory tests
Mild
multicentre
Nasopharyngeal swab
nitazoxanide
not differ
not significantly different
Other
outcome
Patient
Placebo
placebo group
placebo-controlled trial
presenting
Primary outcome
randomised
receive
reduced
resolution of symptoms
reverse transcriptase PCR
Safe
SARS-CoV-2
SARS-COV-2 infection
screened
secondary
secondary outcome
Serious Adverse Event
serum biomarker
significantly
study drug
study visit
Symptom
symptom onset
symptom resolution
therapy
Viral load
viral load reduction
was reduced
[DOI] 10.1183/13993003.03725-2020 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1183/13993003.03725-2020 PMC 바로가기 [Article Type] Randomized Controlled Trial